Sept 6 (Reuters) - British private equity firm Permira

has put its contract drugmaker Cambrex up for sale, targeting a

valuation of as much as $4 billion, the Financial Times reported

on Saturday, citing people familiar with the matter.

Cambrex has been a huge beneficiary of a push by global

drugmakers to shore up their U.S. manufacturing capacity and

domestic inventory due to looming drug import duties proposed by

President Donald Trump, the FT said.

Trump, looking to reverse decades of moving manufacturing

abroad to cut costs, said last month that he plans to impose

phased-in tariffs for the pharmaceutical sector that could

eventually rise to 250%.

Permira bought Cambrex, which provides drug developers with

manufacturing and testing services, for about $2 billion in

2019.

In August, Permira, which manages about 85 billion euros

($99.51 billion) in assets across multiple sectors, made a $3

billion offer for vaccine maker Bavarian Nordic ( BVNKF ) along

with Nordic Capital.

Permira declined to comment. Cambrex did not immediately

respond to a request for comment.

($1 = 0.8542 euros)